Stock Analysis

Asian Market Value Stock Picks For Potential Capital Appreciation

As the Asian markets navigate a landscape marked by mixed performances and economic shifts, investors are closely watching for opportunities amid easing U.S.-China trade tensions and Japan's record stock market highs. In this context, identifying undervalued stocks with strong fundamentals can offer potential for capital appreciation, especially as regional economies adapt to evolving global conditions.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In Asia

NameCurrent PriceFair Value (Est)Discount (Est)
Xi'an International Medical Investment (SZSE:000516)CN¥4.76CN¥9.3849.3%
Visional (TSE:4194)¥9984.00¥19579.1049%
New Zealand King Salmon Investments (NZSE:NZK)NZ$0.195NZ$0.3949.5%
Meitu (SEHK:1357)HK$8.80HK$17.1948.8%
LianChuang Electronic TechnologyLtd (SZSE:002036)CN¥10.08CN¥19.9949.6%
Insource (TSE:6200)¥845.00¥1665.9949.3%
IbidenLtd (TSE:4062)¥13855.00¥27366.1449.4%
Guoquan Food (Shanghai) (SEHK:2517)HK$4.00HK$7.9749.8%
Chongqing Baiya Sanitary Products (SZSE:003006)CN¥22.33CN¥44.0149.3%
Alibaba Health Information Technology (SEHK:241)HK$5.73HK$11.2349%

Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Giant Biogene Holding (SEHK:2367)

Overview: Giant Biogene Holding Co., Ltd. is an investment holding company that designs, develops, manufactures, and sells skin treatment products featuring recombinant collagen in the People's Republic of China, with a market cap of HK$40.87 billion.

Operations: The company's revenue primarily comes from its Personal Products segment, which generated CN¥6.11 billion.

Estimated Discount To Fair Value: 41.8%

Giant Biogene Holding appears undervalued, trading at 41.8% below its estimated fair value of HK$65.51, with a current price of HK$38.16. Recent earnings growth of 27.9% and projected annual profit growth of 17.1% outpace the Hong Kong market average, highlighting strong cash flow potential despite slower revenue growth forecasts at 18.2%. Analysts agree on an expected price rise by 83.4%, reinforcing its relative value compared to peers and industry standards.

SEHK:2367 Discounted Cash Flow as at Nov 2025
SEHK:2367 Discounted Cash Flow as at Nov 2025

Xi'an NovaStar Tech (SZSE:301589)

Overview: Xi'an NovaStar Tech Co., Ltd. designs and develops LED display control solutions both in China and internationally, with a market cap of CN¥15.67 billion.

Operations: The company's revenue is primarily derived from the Video Image Display Control Industry, totaling CN¥3.32 billion.

Estimated Discount To Fair Value: 43.1%

Xi'an NovaStar Tech is trading at 43.1% below its estimated fair value of CNY 304.2, with a current price of CNY 173, highlighting its undervaluation based on cash flows. Despite recent net income declines, earnings are forecast to grow significantly at 29.3% annually, outpacing the Chinese market average and indicating strong future cash flow potential. However, return on equity is expected to be relatively low at 18% in three years.

SZSE:301589 Discounted Cash Flow as at Nov 2025
SZSE:301589 Discounted Cash Flow as at Nov 2025

WT Microelectronics (TWSE:3036)

Overview: WT Microelectronics Co., Ltd. develops and sells electronic and communication components across the United States, Taiwan, China, and other international markets with a market cap of NT$172.73 billion.

Operations: The company's revenue segments include electronic and communication components sales in the United States, Taiwan, China, and other international markets.

Estimated Discount To Fair Value: 43.8%

WT Microelectronics is trading at NT$154, significantly below its estimated fair value of NT$274.12, highlighting its undervaluation based on cash flows. Recent earnings reports show strong performance with net income for Q3 2025 at NT$3.82 billion, up from NT$2.84 billion the previous year. Earnings are projected to grow significantly by 26.9% annually, surpassing Taiwan's market average growth rate and indicating robust future cash flow potential despite high debt levels and modest return on equity forecasts of 16.7%.

TWSE:3036 Discounted Cash Flow as at Nov 2025
TWSE:3036 Discounted Cash Flow as at Nov 2025

Key Takeaways

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com